Page 33 - 21st Century Perspective - Glaucoma Supplement

We have been using Vyzulta in these four scenarios:

● As first-line therapy to reduce IOP as low as possible. Short of hypotony, you really cannot
have too low of an IOP.
● As treatment for patients in whom target IOP is nearly achieved with any of the older
generation prostaglandins. We could easily add a once-daily beta-blocker to the treatment
regimen of these patients, but this would require the acquisition of another topical preserved

eye drop that might not be necessary. (Of course, there is also preservative-free timolol that
could be used if necessary.)
● As therapy for patients who have asthma, or for patients who are nonresponders to
beta-blockers. In these patients, Vyzulta alone might achieve target IOP.
● As a therapy option when a traditional prostaglandin and a beta-blocker come close to but do

not achieve target IOP. Replacing the prostaglandin with Vyzulta might meet treatment
goals.

33